Investors in Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) (TSE:TKM) might be greeted with a rude awakening Thursday morning, as the company missed its earnings estimates and badly whiffed on revenue. Shares of the stock were halted late in the afternoon pending the earnings announcement. In after hours trading, the stock is sharply lower, moving back to test support near the stock’s 200 day moving average, which is currently at $15.87. Tekmira Pharmaceuticals reports second quarter losses Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) (TSE:TKM) reported second quarter earnings per share with a loss of -$0.28, which was $0.02 worse than the analyst estimate loss of -$0.26. Revenue…
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
